COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00947687
Recruitment Status : Completed
First Posted : July 28, 2009
Last Update Posted : September 19, 2017
Retroscreen Virology Ltd.
Quintiles, Inc.
Information provided by (Responsible Party):
Pulmatrix Inc.

Brief Summary:
The objectives of the study are to demonstrate the effectiveness, safety and tolerability of multiple daily doses of inhaled PUR003, in comparison with placebo, in healthy adults experimentally inoculated with Influenza A/Wisconsin/67/2005 (H3N2) virus.

Condition or disease Intervention/treatment Phase
Healthy Drug: PUR003 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Phase 1B, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects
Study Start Date : July 2009
Actual Primary Completion Date : September 2009
Actual Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Arm Intervention/treatment
Experimental: PUR003 Drug: PUR003
Twice-daily (BID) doses of PUR003 will be delivered via inhalation using a commercially available nebulizer for a total of 7 days

Placebo Comparator: Placebo Drug: Placebo

Primary Outcome Measures :
  1. Safety and tolerability of PUR003 as determined by incidence of adverse events (AEs); changes in physical examination, chest examination; pulmonary function; vital signs; electrocardiogram (ECG) and clinical laboratory assessments. [ Time Frame: Day 6 ]

Secondary Outcome Measures :
  1. Subjected-reported symptom scores assessed both individually and as a composite score evaluating severity overall and at the time of peak symptom score [ Time Frame: Day 6 of study ]
  2. Quantitative viral shedding from nasal viral inoculation until day 6 [ Time Frame: Day 0 to day 6 ]
  3. Change in bioaerosol output with treatment and after viral inoculation [ Time Frame: Day -2 to day 6 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male and female subjects aged 18 to 45 years.
  • In general good health determined by a screening evaluation ≤120 days prior to double-blind IMP administration and on the day of admittance to quarantine.
  • Seronegative (NDA) for challenge virus.
  • Have not been vaccinated for influenza virus since 2006 (as determined in the medical history) or had a known influenza infection in the current season, defined as in the last 12 months.

Exclusion Criteria:

  • Presence or evidence of significant acute or chronic, uncontrolled medical or psychiatric illness.
  • Abnormal pulmonary function as evidenced by clinically significant abnormality in spirometry.
  • Health care workers (including doctors, nurses, medical students and allied healthcare professionals) anticipated to have patient contact within two weeks of discharge from quarantine.
  • Intending to travel (to countries for which vaccinations are recommended or where high risk of infections exists).
  • Presence of household member or close contact (until 14 days after discharge from quarantine) who is: less than 3 years of age; has any known immunodeficiency; is receiving immunosuppressant medications; is undergoing or soon to undergo cancer chemotherapy within 28 days of challenge.
  • Subjects with diagnosed emphysema or chronic obstructive pulmonary disease (COPD); elderly residing in a nursing home, affected by severe lung disease or medical condition; or a transplant (bone marrow or solid organ) organ recipient
  • Subjects with any history of asthma, COPD, pulmonary hypertension, reactive airway disease, or any chronic lung condition of any aetiology.
  • Regular daily smokers during the 6 months prior to study entry or those who have a significant history of any tobacco use at any time (≥ total 10 pack year history = one pack a day for 10 years).
  • Presence of any febrile illness or symptoms of upper or lower tract respiratory infection in the 28 days prior to viral inoculation (such subjects may be re-evaluated for enrolment after resolution of the illness).
  • Receipt of any investigational drug within 3 months, or prior participation in a clinical trial of any influenza vaccine or medication within 1 year of participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00947687

Layout table for location information
United Kingdom
Guys Drug Research Unit (GDRU), Quintiles Ltd
London, United Kingdom, SE1 1YR
Sponsors and Collaborators
Pulmatrix Inc.
Retroscreen Virology Ltd.
Quintiles, Inc.
Layout table for investigator information
Study Director: John P Hanrahan, MD Pulmatrix Inc.
Layout table for additonal information
Responsible Party: Pulmatrix Inc. Identifier: NCT00947687    
Other Study ID Numbers: 601-0001P-00
First Posted: July 28, 2009    Key Record Dates
Last Update Posted: September 19, 2017
Last Verified: September 2017
Keywords provided by Pulmatrix Inc.:
healthy subject
virus inoculation
symptom scores
viral shedding
bioaerosol output
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases